Crispr Therapeutics shares tumble after significant earnings miss
Chicago Atlantic Group, LP, a significant shareholder in Vireo Growth Inc. (NASDAQ:VREO), recently acquired additional shares in the company, according to a recent filing. The group purchased a total of 15,000 subordinate voting shares over two consecutive days, with the total transaction amounting to $6,655. The shares were bought at prices ranging from $0.4311 to $0.45 per share, near the middle of its 52-week range of $0.23 to $0.69. According to InvestingPro data, the company currently trades at a market capitalization of $161.6M. Following these transactions, Chicago Atlantic Group now holds 399,272 shares directly. This acquisition reflects the group’s ongoing interest in Vireo Growth, a company classified under pharmaceutical preparations. The company has shown revenue growth of 12.8% over the last twelve months, though InvestingPro analysis indicates it operates with moderate debt levels and maintains a GOOD overall financial health score. Investors should note that the company’s next earnings report is due in 4 days. For deeper insights into VREO’s valuation and financial health metrics, including exclusive ProTips and comprehensive analysis, check out the full Pro Research Report available on InvestingPro.
In other recent news, Vireo Growth Inc. reported a 15.4% increase in full-year revenue, reaching $99.4 million, with fourth-quarter revenue rising 3.5% to $25 million. Despite these gains, the company experienced a fourth-quarter net loss of $15.7 million, primarily due to one-time transaction expenses. Vireo Growth’s strategic initiatives include the development of a new cultivation facility and expansion into adult-use sales in Minnesota, which are expected to drive future growth. The company maintains a strong cash position of $91.6 million, supporting its growth and transformation plans. Analysts have noted that Vireo Growth is focusing on capital deployment in New York and Minnesota, anticipating significant contributions from its New York facility in the second quarter of 2025. The company is also exploring divestiture opportunities for a portion of its New York assets while enhancing its production capabilities. Looking ahead, Vireo Growth projects continued revenue growth, with estimates of $23.9 million in the first and second quarters of 2025, increasing to $29.3 million by the fourth quarter of the same year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.